Revisiting Passive Cooling
As Indian cities battle intensifying heatwaves, can we cool our homes and buildings without ramping up electricity use? In this episode of The Climate Economy from The Hindu, host Kunal Shankar explores the science and solutions behind passive cooling—an age-old yet futuristic way to keep spaces comfortable using design, materials, and nature itself.
From the Urban Heat Island Effect to innovative architectural solutions like double-skin facades, desiccant cooling, PDRC, and thermal mass materials, we look at how buildings can be part of the climate solution rather than the problem.
Featuring global and Indian case studies—from Zimbabwe's termite-inspired EastGate Centre to Delhi's CoolAnt Beehive and Milan's Bosco Verticale—this episode showcases the power of climate-adaptive architecture.
Presentation: Kunal Shankar
Editing: Aniket Singh Chauhan
Script: P Jaisakthi Jothi
Video: Johan Sathya Das
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Hyderabad cardiologist gets US patent for multi-functional cardiac occluder
File photo: Dr Nageswara Rao Koneti HYDERABAD: An innovative device that can fix various types of cardiac defects, designed by Hyderabad-based Dr Nageswara Rao Koneti, who heads the Cardiology Division at Rainbow Children's Heart Institute, has been granted a US patent. Called KONAR-MF Occluder, the multi-functional device can close septal defects in children and adults. It is a double umbrella disc device made of nitinol, a biocompatible nickel and titanium alloy, and is stretchable up to 15 mm. It can treat various conditions, including ventricular septal defects, coronary arteriovenous fistulas, and paravalvular leaks. The device has already been patented in India, Europe (European Commission), Euro-African countries, and South Korea. The multifunctional device not only fixes multiple types of cardiac lesions but also makes advanced cardiac care more affordable for patients in India, as it costs just Rs 50,000 in India compared to Rs 1.2 lakh in Pakistan and Rs 2.5–6 lakhs in other parts of Asia and Europe, said Dr Koneti. Terming this as a proud moment for Indian science, Dr Koneti said: "This US patent validates that innovations from India can meet global standards. It took us over six years to develop the device, and we applied for CE approval in 2018.' He said the US patent now paves the way for a US FDA (US Food and Drug Administration) approval for the device, which has already been implanted in about 10-15 patients in the US on compassionate grounds. "But we can also do clinical trials in the US if required," said Dr Koneti, who is a paediatric interventional cardiologist. He pointed out that the device has already demonstrated its safety and efficacy through over 20 peer-reviewed studies, and over 10,000 of these devices have already been implanted in patients in over 90 countries across Asia, Europe, Latin America, and Africa since the device got CE approval in 2018. The device is manufactured by LifeTech Scientific of China. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
India Today
3 hours ago
- India Today
Isro chief reviews prep ahead of Indian astronaut's launch to space
With just days remaining until the launch of the landmark Axiom Mission 4 (Ax-4), Indian Space Research Organisation (Isro) chief V Narayanan visited Axiom Space's Houston facilities.,Axiom Space will launch Indian astronaut Shubhanshu Shukla on 14-day mission to the Space Station on June visit by the Indian space agency chief focused on Axiom's manufacturing and technical capabilities, as both organisations prepare for India's return to human spaceflight after more than four decades. advertisement The Ax-4 mission, now scheduled for launch on June 10, 2025, will see Group Captain Shubhanshu Shukla become only the second Indian to travel to space, and the first to visit the International Space Station (ISS).Shukla, serving as mission pilot, will join commander Peggy Whitson (USA), and mission specialists Sawosz Uznaski-Winiewski (Poland) and Tibor Kapu (Hungary) for a 14-day scientific mission aboard the the Isro Chairman's tour, Axiom Space leadership reiterated their commitment to supporting Isro's space ambitions. Days away from our historic #Ax4 human spaceflight mission, the ISRO Chairman visited the full complement of Axiom Space facilities with a focus on our team's manufacturing and technical expertise. We are committed to supporting ISRO's space endeavors Ax-4 and beyond! Axiom Space (@Axiom_Space) June 4, 2025The Ax-4 mission will conduct around 60 scientific studies involving 31 countries, with Isro selecting seven microgravity experiments in fields such as agriculture, food science, and human efforts are expected to provide critical experience for India's upcoming Gaganyaan mission and future space station Isro Chairman's visit marks a significant milestone in India's growing role in global space exploration and signals a new era of public-private collaboration in advancing human spaceflight. Must Watch
Indian Express
3 hours ago
- Indian Express
A father-son legacy of Padma honors and pioneering scientific research
Written by Siddhi Patil, Dr Chetan Eknath Chitnis, a globally renowned Indian scientist, has dedicated his life to combating malaria, a persistent global health challenge claiming countless lives annually. His groundbreaking work in malaria vaccine development has earned him the prestigious Padma Shri this year, alongside awards like the Shanti Swarup Bhatnagar Award and the Infosys Prize. Remarkably, Dr. Chitnis shares a rare distinction with his father, Eknath Vasant Chitnis, a Padma Bhushan recipient (1985) and a founding member of the Indian Space Research Organisation (ISRO). This rare father-son duo's Padma honors reflect a deep family legacy of scientific excellence, with both making transformative contributions to their respective fields. Dr. Chitnis's journey in medical research is deeply rooted in his upbringing. His father, a distinguished space scientist and former director of ISRO's Space Application Centre, instilled a passion for dedicated work. 'My father taught me that true commitment means loving what you do, no matter the hours,' Dr. Chitnis recalls. While he initially pursued physics, inspired by his father's rigor, it was his mother, a biochemist focused on cancer research, who steered him toward biology. This pivot led him to lead the Malaria Parasite Biology and Vaccines Unit at Institut Pasteur in Paris, where he drives innovative vaccine research to curb malaria's devastating impact. Pune holds a special place in Dr. Chitnis's heart. Childhood summers spent at his grandparents' home in Deccan Gymkhana, exploring nearby hills with cousins, evoke memories of a serene, green Pune. His parents' decision to settle in the city post-retirement deepened his connection. Today, as Pune evolves into a bustling hub of innovation, Dr. Chitnis is eager to engage with its academic and research communities, blending personal nostalgia with professional aspirations. From IIT Bombay to UC Berkeley, the National Institutes of Health, and the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi, Dr. Chitnis's career spans continents. His work at ICGEB, supported by robust government backing, laid the foundation for his current efforts in Paris. A significant breakthrough came during the COVID-19 pandemic when delayed vaccine trials at Oxford revealed that a 14-month gap between doses reduced malaria parasite growth—an unexpected finding inspired by similar COVID-19 vaccine insights. This discovery, coupled with advancements in mRNA technology, fuels his cautious optimism for future malaria solutions. The Padma Shri holds deep significance for Dr. Chitnis. 'Being recognised by my homeland, even after a decade abroad, is humbling,' he says. He views the award as a tribute to his team's collective efforts and a call to continue serving society.
